| The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment |
Recruiting |
Colorectal Cancer|Drug Resistance|Mass Spectrometry|RAS-RAF Pathway Deregulation |
NCT03401957 |
| Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate |
Recruiting |
Head and Neck Squamous Cell Carcinoma|Margin Assessment |
NCT03134846 |
| Cetuximab in Head and Neck Cancer Patients |
Suspended |
Head and Neck Cancer|Squamous Cell Carcinoma |
NCT03769311 |
| Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer |
Active, not recruiting |
Rectal Cancer Stage III |
NCT03391843 |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss |
Active, not recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT02822482 |
| Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery |
Terminated |
Pancreatic Adenocarcinoma |
NCT02736578 |
| Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer |
Recruiting |
Cancer of Colon |
NCT03524820 |
| Cetuximab Rechallenge Study |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT01832467 |
| Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer |
Completed |
Recurrent Head and Neck Cancer |
NCT01255800 |
| Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer |
Recruiting |
Metastatic Colorectal Cancer |
NCT02117466 |
| Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures |
Terminated |
Head and Neck Cancer |
NCT01987375 |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
Completed |
Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head And Neck |
NCT02277197 |
| An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck |
Terminated |
Carcinoma, Squamous Cell |
NCT01142869 |
| Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer |
Recruiting |
Drug Safety |
NCT04161560 |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy |
Active, not recruiting |
Advanced Cancers |
NCT02095054 |
| Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects |
Unknown status |
Colorectal Cancer Metastatic|C-met Overexpression |
NCT01892527 |
| Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients |
Not yet recruiting |
Colorectal Cancer|ADCC |
NCT03874026 |
| Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab |
Completed |
Colorectal Cancer Metastatic |
NCT01382407 |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) |
Withdrawn |
Squamous Cell Carcinoma of the Penis |
NCT02014831 |
| Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
NCT02499120 |
| Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection |
Recruiting |
Tumor Disease Including Colorectal Cancer|Head & Neck Squamous Cell Carcinoma |
NCT03485638 |
| Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer |
Recruiting |
Colorectal Neoplasms|Solid Tumors |
NCT02953782 |
| Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer |
Recruiting |
Recurrent Skin Cancer|Squamous Cell Carcinoma of the Skin |
NCT02324608 |
| Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy |
Unknown status |
Adenoid Cystic Carcinoma |
NCT01192087 |
| sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories |
Recruiting |
High Risk, Locally-advanced Squamous Cell Carcinoma of Head and Neck |
NCT04091867 |
| Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck |
Unknown status |
Squamous Cell Carcinoma of the Head and Neck |
NCT01830556 |
| Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer |
Recruiting |
Head and Neck Squamous Cell Cancer|Recurrent Head and Neck Squamous Cell Cancer|Metastatic Head and Neck Squamous Cell Cancer |
NCT03667482 |
| Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection |
Completed |
Pancreatic Cancer |
NCT02241187 |
| Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01919879 |
| Palbociclib and Cetuximab in Metastatic Colorectal Cancer |
Recruiting |
Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer|Neoplasms, Colonic |
NCT03446157 |
| Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer |
Completed |
Head and Neck|Squamous Cell Cancer |
NCT00661427 |
| A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients |
Recruiting |
Metastatic Colorectal Cancer |
NCT03391934 |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
Recruiting |
HNSCC|Lip SCC|Oral Cavity Cancer|Oropharynx Cancer|Larynx Cancer|Hypopharynx Cancer|Nasopharynx Cancer|Sinonasal Carcinoma|Cutaneous Squamous Cell Carcinoma|Head and Neck Neoplasms|Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma |
NCT03082534 |
| Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00422773 |
| Lapatinib and Cetuximab in Patients With Solid Tumors |
Completed |
Colorectal Cancer|Lung Cancer|Head and Neck Cancer |
NCT01184482 |
| A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab |
Completed |
Oropharyngeal Cancer|Hypopharyngeal Cancer|Laryngeal Cancer |
NCT01435252 |
| Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
Head and Neck Cancer |
NCT01979211 |
| A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma |
Recruiting |
Advanced Head and Neck Squamous Cell Carcinoma |
NCT03254927 |
| Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT01012258 |
| Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer |
Recruiting |
Colon Cancer|Colo-rectal Cancer |
NCT03774680 |
| Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01251536 |
| Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma |
Terminated |
Squamous Cell Carcinoma Of The Head And Neck |
NCT01488318 |
| Study of Sorafenib/Cetuximab in Head and Neck Cancer |
Completed |
Squamous Cell Cancer |
NCT00815295 |
| Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer |
Unknown status |
Colorectal Neoplasms|Neoplasm Metastasis|Liver Neoplasms |
NCT01564810 |
| Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma |
Active, not recruiting |
Thymoma|Thymic Carcinoma|Clinical Masaoka Stage II to IVA |
NCT01025089 |
| Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer |
Recruiting |
Skin Squamous Cell Carcinoma|Metastatic Skin Cancer |
NCT03944941 |
| Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer |
Withdrawn |
Colorectal Cancer |
NCT01960023 |
| Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Cancer, Squamous Cell|Cetuximab Effect|Chemotherapy Effect |
NCT03126708 |
| CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer |
N/A |
N/A |
NCT01760811 |
| A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers |
Completed |
Colorectal Cancer|Squamous Cell Head and Neck Cancer|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Other Tumors With EGFR Dependence |
NCT01451632 |
| Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan |
Terminated |
Colorectal Cancer |
NCT01004159 |
| Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcÎłRIIa (CD32) Genotype |
Completed |
Colorectal Neoplasms |
NCT01450319 |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA |
Completed |
Glioblastoma Multiforme (GBM)|ANAPLASTIC ASTROCYTOMA (AOA)|GBM|Anaplastic Astrocytoma |
NCT01238237 |
| Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients |
Completed |
Stage IV Cancer |
NCT00691548 |
| Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer |
Recruiting |
Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Tongue Cancer |
NCT02177838 |
| An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment |
Terminated |
Colorectal Neoplasm |
NCT01074333 |
| Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Active, not recruiting |
Recurrent|Head and Neck Cancer |
NCT02057107 |
| Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01051167 |
| FOLFOX-Cetuximab-radiotherapy for the Treatment of Esophageal Cancer |
Completed |
Esophageal Cancer Stage III |
NCT00578201 |
| A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer |
Recruiting |
Colorectal Cancer |
NCT04241731 |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
Recruiting |
Squamous Cell Carcinoma of the Oropharynx|Squamous Cell Carcinoma of the Larynx|Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Hypopharynx|Squamous Cell Carcinoma of the Paranasal Sinus|Head and Neck Squamous Cell Carcinoma|Squamous Cell Cancer|Head and Neck Carcinoma |
NCT03370276 |
| Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib |
Completed |
Lung Adenocarcinoma |
NCT00716456 |
| Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. |
Recruiting |
Cancer Colorectal |
NCT04189055 |
| Cetuximab for Elderly Patients With mCRC |
Terminated |
Metastatic Colorectal Cancer |
NCT01718808 |
| Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer |
Unknown status |
Head and Neck Neoplasms |
NCT02817113 |
| Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
Carcinoma, Squamous Cell|Carcinoma, Squamous Cell of Head and Neck |
NCT02438995 |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT04278092 |
| A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors |
Terminated |
Colorectal Cancer|Head and Neck Cancer |
NCT01871311 |
| Study of XELOX With Cetuximab in Advanced Gastric Cancer |
Completed |
Gastric Cancer |
NCT00398398 |
| Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03498378 |
| Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma |
Completed |
Head and Neck Cancer |
NCT00968435 |
| Adjuvant Cetuximab and Chemoradiation in Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00791141 |
| Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC |
Completed |
Non Small Cell Lung Cancer (NSCLC) |
NCT00492206 |
| Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design |
Recruiting |
Squamous Cell Carcinoma |
NCT02128906 |
| Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer |
NCT02845856 |
| Induction and Concurrent Chemoradiotherapy With Cetuximab for Patients With Locally Advanced Nasopharyngeal Carcinoma |
Terminated |
Nasopharyngeal Carcinoma |
NCT01230476 |
| A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT02054442 |
| A Phase 2a/2b Multicenter, Open-Label Study to Evaluate NKTR 102 in Combination With Cetuximab Versus Irinotecan in Combination With Cetuximab in Second Line Colorectal Cancer Patients |
Completed |
Tumor|Colorectal Cancer |
NCT00598975 |
| Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT01309126 |
| Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy |
Terminated |
Non-small Cell Lung Cancer |
NCT00694603 |
| A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC |
Terminated |
Head and Neck Cancer |
NCT00882583 |
| Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma |
Completed |
Hepatocellular Carcinoma |
NCT00142428 |
| Trial of Cetuximab in Patients With Metastatic and/or Locally Advanced Soft Tissue and Bony Sarcomas |
Completed |
Sarcoma |
NCT00148109 |
| Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) |
Completed |
HEAD & NECK Cancer |
NCT00736619 |
| Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy |
Completed |
Nasopharyngeal Carcinoma |
NCT00700440 |
| Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea |
Completed |
Head and Neck Cancer |
NCT01075828 |
| Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma |
Withdrawn |
Squamous Cell Cancer of the Head and Neck |
NCT00934518 |
| RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab |
Unknown status |
Colorectal Cancer Metastatic |
NCT01943786 |
| Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery |
Completed |
Head and Neck Cancer |
NCT00714649 |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck |
NCT02124707 |
| Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer |
Completed |
Stage IV Non-small Cell Lung Cancer |
NCT01004731 |
| Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer |
Recruiting |
Carcinoma, Non-Small-Cell Lung |
NCT03727724 |
| Sirolimus and Cetuximab in Advanced Malignancies |
Completed |
Advanced Cancer |
NCT00940381 |
| A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
NCT00409565 |
| EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
NCT03494322 |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer |
Recruiting |
Nasopharyngeal Cancer|Head and Neck Squamous Cell Carcinoma |
NCT02507154 |
| Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC |
Active, not recruiting |
Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
NCT01864772 |
| Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors |
Completed |
Breast Cancer|Colorectal Cancer|Head and Neck Cancer|Kidney Cancer|Lung Cancer|Pancreatic Cancer|Sarcoma|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00622674 |
| Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer |
Terminated |
Head and Neck Neoplasms|Laryngeal Neoplasms|Mouth Neoplasms|Pharyngeal Neoplasms |
NCT01216020 |
| Erlotinib in Combination With Cetuximab |
Completed |
Advanced Cancers |
NCT00895362 |
| Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR |
Completed |
Skin Diseases|Carcinoma, Squamous Cell |
NCT00240682 |
| Phase 1 and 2 Study of PX-866 and Cetuximab |
Completed |
Incurable Metastatic Colorectal Carcinoma|Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
NCT01252628 |
| AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer |
Completed |
Colonic Neoplasms|Cancer of the Colon|Colon Cancer|Colon Neoplasms|Colonic Cancer |
NCT01287130 |
| A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer |
Completed |
Colon Rectal Cancer Duke Stage Stageval |
NCT01310985 |
| Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors |
Completed |
Advanced Cancer |
NCT00698841 |
| Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT01034189 |
| Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux |
Recruiting |
Healthy Volunteers |
NCT03881787 |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 |
Recruiting |
Glioblastoma Multiforme|Fibrillary Astrocytoma of Brain|Glioma of Brainstem|Anaplastic Astrocytoma|Pilomyxoid Astrocytoma|Mixed Oligodendroglioma-Astrocytoma|Brain Stem Glioma|Diffuse Intrinsic Pontine Glioma |
NCT01884740 |
| EMMA-1 (Erbitux for Multiple Myeloma) |
Terminated |
Multiple Myeloma |
NCT00368121 |
| Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis |
Recruiting |
Colorectal Cancer Stage IV|Metastasis |
NCT03031444 |
| A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients |
Terminated |
Colon Cancer |
NCT00494611 |
| Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1Âş Chemotherapy |
Terminated |
Head and Neck Cancer |
NCT03887442 |
| Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer |
Completed |
Lung Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00408499 |
| CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer |
Unknown status |
Carcinoma, Squamous Cell of Head and Neck |
NCT02052960 |
| RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN |
Terminated |
Head and Neck Cancer |
NCT01009346 |
| Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer |
Not yet recruiting |
Colorectal Cancer |
NCT04262635 |
| A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing Treatment |
Completed |
Colorectal Neoplasms |
NCT01082315 |
| A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer |
Completed |
Head and Neck Cancer|Colon Cancer |
NCT01744340 |
| EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-NaĂŻve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
Squamous Cell Carcinoma of the Head and Neck Cancer |
NCT01040832 |
| Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT01716416 |
| Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer |
Completed |
Carcinoma, Squamous Cell |
NCT00671437 |
| Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer |
Completed |
Lung Cancer |
NCT00103207 |
| Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery |
Terminated |
Brain Neoplasm|Malignant Glioma |
NCT02855086 |
| ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT01218048 |
| Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00232505 |
| A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT01032291 |
| Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer |
Completed |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma |
NCT01581970 |
| Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients |
Unknown status |
Rectum Cancer |
NCT00964457 |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC |
Not yet recruiting |
Colorectal Cancer |
NCT02942706 |
| A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Terminated |
Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|LA SCCHN |
NCT01303237 |
| Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer |
Not yet recruiting |
Head and Neck Neoplasms |
NCT03051906 |
| Cetuximab Monotherapy Maintenance Treatment in mCRC |
Unknown status |
Colorectal Cancer |
NCT02978313 |
| Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis |
Completed |
Colorectal Cancer|Unresectable Liver Metastasis |
NCT00743678 |
| PD 0332991 and Cetuximab in Patients With Incurable SCCHN |
Recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT02101034 |
| Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck |
Unknown status |
Head and Neck Neoplasms |
NCT02015650 |
| Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer |
Withdrawn |
Colorectal Cancer |
NCT02630420 |
| Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer |
Completed |
Cervical Squamous Cell Carcinoma|Recurrent Cervical Carcinoma |
NCT00499031 |
| Erbitux MEtastatic Colorectal Cancer Strategy Study |
Recruiting |
Antineoplastic Agents |
NCT02484833 |
| Efficacy of Cetuximab in Combination With Irinotecan and 5- FU/FA in Treatment of Metastatic Gastric Cancer |
Completed |
Adenocarcinoma of Stomach or Esophagogastric Junction |
NCT01123811 |
| Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
Recruiting |
Locally Advanced Thoracic Middle-lower Segment Esophageal Squamous Cell Carcinoma |
NCT02123381 |
| Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) |
Active, not recruiting |
Squamous Cell Anal Carcinoma |
NCT03944252 |
| Docetaxel and Cetuximab in Treating Patients With Metastatic Prostate Cancer |
Completed |
Prostate Cancer |
NCT00728663 |
| Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). |
Unknown status |
Metastatic Colorectal Cancer |
NCT02296203 |
| Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma |
Completed |
Nasopharyngeal Carcinoma |
NCT01271439 |
| Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer |
Completed |
Esophageal Cancer|Gastric Cancer|Neoplasm Metastasis |
NCT00130689 |
| An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer |
Terminated |
Colorectal Neoplasms |
NCT01134666 |
| S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer |
Completed |
Esophageal Cancer |
NCT00096031 |
| Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC) |
Completed |
Lung Cancer |
NCT00673738 |
| Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT01104922 |
| Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
Carcinoma of the Head and Neck |
NCT00865098 |
| A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer |
Unknown status |
Colorectal Neoplasms |
NCT02717923 |
| A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma |
Unknown status |
Metastatic Colorectal Cancer |
NCT00931840 |
| Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck |
Recruiting |
Squamous Cell Cancers of the Head and Neck |
NCT02979977 |
| Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) |
Completed |
Nasopharyngeal Carcinoma |
NCT01712919 |
| Cetuximab + Gemox in Biliary Tract Cancer |
Completed |
Unresectable|Locally Advanced|Metastatic |
NCT01216345 |
| Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00225784 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations |
Completed |
Metastatic Colorectal Cancer |
NCT02278133 |
| NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
Carcinoma, Squamous Cell of Head and Neck |
NCT03109158 |
| Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00871169 |
| Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
Completed |
Squamous Cell Head and Neck Carcinoma|Recurrent or Metastatic Disease |
NCT01289522 |
| Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC) |
Completed |
Metastatic Colorectal Cancer |
NCT01281761 |
| Cetuximab and Lenalidomide in Head and Neck |
Completed |
Squamous Cell Carcinoma |
NCT01133665 |
| BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00326495 |
| Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) |
Completed |
Cancer of Head and Neck |
NCT00343083 |
| Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer |
Completed |
Endometrial Cancer |
NCT00392769 |
| Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT02404935 |
| External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas |
Active, not recruiting |
Brain Cancer |
NCT01012609 |
| A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck |
Withdrawn |
Neoplasms, Squamous Cell |
NCT01075841 |
| Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma |
Recruiting |
Head and Neck Cancer|Locally Advanced |
NCT03024489 |
| Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT03914170 |
| Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) |
Withdrawn |
Head and Neck Cancer |
NCT01427205 |
| Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) |
Completed |
Non-Small Cell Lung Cancer (NSCLC) |
NCT00820755 |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer |
Unknown status |
Metastatic Colorectal Cancer |
NCT02063529 |
| Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy |
Completed |
Colorectal Neoplasms|Metastases|Neoplasm |
NCT00083720 |
| A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer |
Completed |
Head and Neck Neoplasms|Cancer of the Head and Neck |
NCT01283334 |
| Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Recruiting |
Recurrent Head and Neck Cancer|Head and Neck Cancer|Head and Neck Neoplasms|Metastatic Cancer |
NCT03691714 |
| Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma |
Unknown status |
Cancer of the Cervix |
NCT00292955 |
| Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma |
Terminated |
Esophageal Adenocarcinoma |
NCT00430027 |
| Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer |
Completed |
Recurrent Colon Carcinoma|Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Rectal Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Verrucous Carcinoma AJCC v7|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVA Major Salivary Gland Cancer AJCC v7|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVA Oral Cavity Cancer AJCC v6 and v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Verrucous Carcinoma AJCC v7|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVB Major Salivary Gland Cancer AJCC v7|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVB Oral Cavity Cancer AJCC v6 and v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Rectal Cancer AJCC v7|Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVC Laryngeal Verrucous Carcinoma AJCC v7|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7|Stage IVC Major Salivary Gland Cancer AJCC v7|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7|Stage IVC Oral Cavity Cancer AJCC v6 and v7|Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7|Tongue Carcinoma |
NCT01254617 |
| E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck |
Completed |
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck |
NCT01332266 |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib |
Withdrawn |
Advanced Cancers |
NCT01432119 |
| Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer |
Completed |
Bladder Cancer |
NCT00645593 |
| Cetuximab in Treating Patients With Advanced Solid Tumors |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00376727 |
| Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer |
Completed |
Non-Small Cell Lung Cancer |
NCT00216203 |
| Cisplatin Chemoradiation With or Without Cetuximab for Locoregionally Advanced Squamous Cell Carcinomas (SCC) of the Head and Neck |
Unknown status |
Head and Neck Neoplasms|AJCC Stage III/IV |
NCT01301248 |
| A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer |
Unknown status |
Carcinoma, Squamous Cell |
NCT00660218 |
| Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer |
Withdrawn |
Metastatic Colorectal Cancer |
NCT00954876 |
| Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients |
Withdrawn |
Head and Neck Squamous Cell Carcinoma |
NCT02143622 |
| Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer |
Unknown status |
Rectal Cancer |
NCT00689702 |
| A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab |
Terminated |
Squamous Cell Carcinoma of the Head and Neck |
NCT02124850 |
| Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck |
Completed |
Head and Neck Cancer |
NCT00617734 |
| Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine |
Completed |
Pancreatic Cancer |
NCT00923299 |
| Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients. |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT04229459 |
| A Study of Mitomycin C, Irinotecan, and Cetuximab |
Terminated |
Colorectal Cancer |
NCT00271011 |
| ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01001377 |
| Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors |
Completed |
Cancer|Refractory Solid Tumor |
NCT00110357 |
| Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma |
Recruiting |
Head and Neck Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma|Head and Neck Cancer|Head and Neck Carcinoma |
NCT03524326 |
| Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer |
Completed |
Esophageal Cancer |
NCT01787006 |
| Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT01758731 |
| Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery |
Completed |
Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Carcinoma |
NCT01696955 |
| FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema |
Unknown status |
Colorectal Cancer Metastatic |
NCT01315990 |
| Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination |
Completed |
Neoplasms |
NCT01973868 |
| Comparative Study of Cetuximab and Radiation Vs Surgery Before or After Radiation in Patients With Colorectal Carcinoma |
Withdrawn |
Colorectal Carcinoma |
NCT00725400 |
| Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer |
Completed |
Gastric Cancer |
NCT00275951 |
| ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00436072 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer |
NCT01334177 |
| Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer. |
Withdrawn |
Metastatic Colorectal Cancer |
NCT03688230 |
| Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer |
Completed |
Colorectal Cancer|Head and Neck Cancer |
NCT02110082 |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma |
Recruiting |
Head and Neck Basaloid Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Squamous Cell Carcinoma of Unknown Primary Origin|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IV Oropharyngeal Squamous Cell Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Head and Neck Cancer|Oropharyngeal Cancer|HNSCC|Stage IV Lip and Oral Cavity Squamous Cell Carcinoma |
NCT03422536 |
| Boron Neutron Capture Therapy (BNCT) Combined With Cetuximab in the Treatment of Locally Recurred Head and Neck Cancer |
Terminated |
Head and Neck Cancer |
NCT00927147 |
| Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients |
Unknown status |
Colorectal Cancer|Liver Metastases |
NCT01322178 |
| Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib |
Completed |
Colorectal Cancer|Head and Neck Cancer|Non Small Cell Lung Cancer (NSCLC) |
NCT00820417 |
| Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00291707 |
| Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors |
Unknown status |
Patients With Advanced or Metastatic Solid Tumors |
NCT02215720 |
| Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer |
Terminated |
Non-small Cell Lung Cancer |
NCT00203931 |
| Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum |
Terminated |
Rectal Cancer |
NCT00580073 |
| A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT01177956 |
| Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer |
Completed |
Non-small Cell Lung Cancer |
NCT00165334 |
| Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy |
Completed |
Colon Cancer|Rectum Cancer |
NCT00336856 |
| Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer |
Terminated |
Rectal Cancer |
NCT00611858 |
| A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer |
Completed |
Colorectal Neoplasms |
NCT00055419 |
| Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer |
Terminated |
Head and Neck Squamous Cell Cancer |
NCT01326923 |
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab |
Terminated |
Head and Neck Cancer |
NCT00319839 |
| Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer |
Unknown status |
Head and Neck Neoplasms |
NCT01020864 |
| Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC |
Unknown status |
Oropharyngeal Squamous Cell Carcinoma |
NCT01874171 |
| Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours |
Completed |
Metastatic Colorectal Cancer |
NCT01161316 |
| A Phase II Trial of Modified FOLFOX 6 and Cetuximab in First Line Treatment of Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00251485 |
| Study of Cetuximab to Treat Gastric Cancer |
Completed |
Gastric Cancer |
NCT00699881 |
| Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer |
Terminated |
Head and Neck Squamous Cell Cancer |
NCT01790516 |
| Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer|Unspecified Adult Solid Tumor, Protocol Specific |
NCT01217450 |
| Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study |
Terminated |
Colorectal Cancer Metastatic |
NCT02316496 |
| Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00522665 |
| Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer |
Completed |
Gastric Cancer|Precancerous Condition |
NCT00477880 |
| Preoperative Treatment With Cetuximab and/or IMC-A12 |
Completed |
Head and Neck Squamous Cell Carcinoma |
NCT00957853 |
| Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors |
Terminated |
Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis |
NCT00908024 |
| Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer |
Unknown status |
Epidermoid Head and Neck Cancer |
NCT01647555 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer |
Recruiting |
BRAF NP_004324.2:p.V600E|Metastatic Colon Adenocarcinoma|Metastatic Microsatellite Stable Colorectal Carcinoma|Metastatic Rectal Adenocarcinoma|Progressive Disease|Recurrent Colorectal Carcinoma|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8|Unresectable Colon Adenocarcinoma|Unresectable Rectal Adenocarcinoma |
NCT04017650 |
| A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients |
Completed |
Metastatic Colorectal Cancer |
NCT01228734 |
| Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum |
NCT01294826 |
| A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab |
Terminated |
Colon Cancer|Rectal Cancer |
NCT00845039 |
| TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT01060423 |
| Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer |
Terminated |
Head and Neck Cancer |
NCT00891904 |
| Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer |
Terminated |
Colorectal Cancer Metastatic|Skin Toxicity |
NCT01317433 |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01719380 |
| Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer |
Active, not recruiting |
Non Small Cell Lung Cancer |
NCT02716311 |
| Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors |
Completed |
Neoplasms |
NCT00207077 |
| TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer |
Completed |
Head and Neck Cancer |
NCT00765011 |
| Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma |
Unknown status |
Breast Neoplasms |
NCT00353717 |
| Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab |
Completed |
Colon Cancer|Head and Neck Cancer|Allergic Reaction |
NCT01436617 |
| Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma |
Active, not recruiting |
HPV Positive Oropharyngeal Squamous Cell Carcinoma |
NCT01855451 |
| Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) |
Completed |
Metastatic Colorectal Cancer |
NCT00778830 |
| Novel Treatment Option for Neuropathic Pain |
Completed |
Neuralgia|Complex Regional Pain Syndromes |
NCT02490436 |
| A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma |
Completed |
Esophageal Carcinoma |
NCT00733889 |
| Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00305760 |
| Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00034541 |
| Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study |
Completed |
Squamous Cell Cutaneous Carcinoma of the Skin |
NCT03325738 |
| Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer |
Completed |
Urologic Neoplasm |
NCT00350025 |
| Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy |
Completed |
Colorectal Cancer |
NCT00503685 |
| A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT00383149 |
| A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. |
Completed |
Cancer |
NCT00996567 |
| Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer |
Terminated |
Gastric Cancer |
NCT01611506 |
| Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma |
Terminated |
Resectable Esophageal Cancer |
NCT00827671 |
| Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours |
Completed |
Neoplasms |
NCT02020577 |
| Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery |
Active, not recruiting |
Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer |
NCT02713373 |
| Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study |
Completed |
Time to Progression |
NCT00747097 |
| LEAC-102 for Advanced Colorectal Cancer |
Not yet recruiting |
Advanced Colorectal Cancer |
NCT02826837 |
| Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy |
Withdrawn |
Esophageal Carcinoma |
NCT00636298 |
| Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab |
Completed |
Colorectal Cancer |
NCT01276379 |
| Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer |
Active, not recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT02383966 |
| A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) |
Completed |
Carcinoma, Squamous Cell of Head and Neck |
NCT01080066 |
| Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) |
Completed |
Androgen-independent Prostate Cancer |
NCT00661492 |
| Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00089297 |
| Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC |
Terminated |
Lung Cancer |
NCT00519831 |
| FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00145314 |
| Preoperative Chemoradiation With Capecitabine and Cetuximab |
Completed |
Rectal Cancer |
NCT00297128 |
| Neo-Adjuvant Study in Triple Negative Breast Cancer Patients |
Active, not recruiting |
Breast Cancer |
NCT01097642 |
| Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy |
Withdrawn |
Lung Cancer |
NCT00998101 |
| Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) |
Completed |
Carcinoma, Squamous Cell of Head and Neck |
NCT02938273 |
| Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00124618 |
| TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer. |
Completed |
Head and Neck Cancer |
NCT00716391 |
| Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors |
Unknown status |
Solid Tumors |
NCT01166035 |
| Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer |
Completed |
Triple Negative Locally Advanced Non-resectable Breast Cancer|Metastatic Breast Cancer |
NCT00633464 |
| Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer |
Completed |
Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Small Cell Carcinoma|Cervical Squamous Cell Carcinoma|Stage IB Cervical Cancer|Stage IIA Cervical Cancer|Stage IIB Cervical Cancer|Stage III Cervical Cancer|Stage IVA Cervical Cancer |
NCT00104910 |
| Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors |
Terminated |
Metastatic Colorectal Cancer |
NCT01858662 |
| Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
Completed |
Colorectal Cancer Metastatic |
NCT01640444 |
| Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) |
Completed |
Non Small Cell Lung Cancer (NSCLC) |
NCT00148798 |
| A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00162318 |
| Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab |
Terminated |
Laryngeal Neoplasms |
NCT00941135 |
| Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer |
Terminated |
Metastatic Pancreatic Cancer |
NCT00326911 |
| Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00468169 |
| A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC |
Completed |
Cholangiocarcinoma|Adenocarcinoma of Gallbladder |
NCT01267344 |
| Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer |
Completed |
Cancer |
NCT00703976 |
| 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX |
Terminated |
Rash |
NCT01692626 |
| Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM |
Recruiting |
Colo-rectal Cancer|Liver Metastases |
NCT03493048 |
| Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) |
Active, not recruiting |
Head and Neck Squamous Cell Cancer |
NCT02282371 |
| A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces |
Completed |
Mucinous Gastrointestinal Adenocarcinoma |
NCT00162110 |
| Phase I Cetuximab and Concurrent Radio-chemotherapy |
Completed |
Non-small Cell Lung Cancer |
NCT00522886 |
| Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. |
Completed |
Previously Untreated Metastatic Colorectal Cancer |
NCT00439517 |
| Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas |
Recruiting |
Glioblastoma |
NCT03603379 |
| Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0 |
Completed |
Locally Advanced Cancer in the Anal Region |
NCT01621217 |
| Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery |
Completed |
Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer |
NCT01107639 |
| Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT01090011 |
| Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With Squamous Non-small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Squamous Non-Small Cell Lung Cancer |
NCT03717155 |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
Completed |
Colon Cancer Adenocarcinoma |
NCT02022995 |
| Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. |
Completed |
Colorectal Cancer |
NCT01068132 |
| FIVC in Advanced Colorectal Cancer Patients With BRAF V600E Mutation. |
Recruiting |
Colorectal Cancer |
NCT03727763 |
| Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient |
Completed |
Metastatic Colorectal Cancer |
NCT02295930 |
| Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy |
Terminated |
Squamous Cell Carcinoma of Head and Neck (SCCHN)|Metastatic Colorectal Cancer |
NCT02205398 |
| Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) |
Active, not recruiting |
Head and Neck Cancer |
NCT00904345 |
| PETACC-8 miR-31-3p and miR-31-5p Ancillary Study |
Completed |
Colorectal Cancer |
NCT03362684 |
| Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00713219 |
| Pre-op Rectal ChemoRad +/- Cetuximab |
Completed |
Rectal Cancer |
NCT00527111 |
| A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00343291 |
| Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage III Adenoid Cystic Carcinoma of the Oral Cavity|Stage III Basal Cell Carcinoma of the Lip|Stage III Colon Cancer|Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage III Lymphoepithelioma of the Nasopharynx|Stage III Lymphoepithelioma of the Oropharynx|Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage III Mucoepidermoid Carcinoma of the Oral Cavity|Stage III Pancreatic Cancer|Stage III Rectal Cancer|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IIIB Non-small Cell Lung Cancer|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Renal Cell Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT00101348 |
| Reirradiation and Erbitux in the HNSCC |
Completed |
Head and Neck Cancer Squamous Cell |
NCT01237483 |
| Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy |
Completed |
Metastatic Colorectal Cancer |
NCT01225744 |
| Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer |
Completed |
Gastric Cancer |
NCT01388790 |
| S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer |
Active, not recruiting |
Colorectal Cancer |
NCT02164916 |
| Nebraska |
Henderson |
United States|Comprehensive Cancer Centers of Nevada - Henderson |
Scottsbluff |
| Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma |
Terminated |
Squamous Cell Carcinoma|Head and Neck Cancer|Recurrent Disease |
NCT01794845 |
| Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM) |
Completed |
Colorectal Cancer|Liver Metastases |
NCT00153998 |
| Irinotecan and Cetuximab in Treating Patients With Metastatic Breast Cancer |
Completed |
Breast Cancer |
NCT00275041 |
| Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver |
Withdrawn |
Colon Cancer|Colorectal Cancer |
NCT00766220 |
| A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025) |
Completed |
Rectal Neoplasms |
NCT01609231 |
| Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer |
Completed |
Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer |
NCT01445405 |
| ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01075048 |
| Treatment Selection According to Skin Reaction to Cetuximab |
Unknown status |
Head and Neck Cancer |
NCT01472653 |
| MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases |
Recruiting |
Oral Cancer|Lymph Node Metastases |
NCT03923881 |
| Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer |
Completed |
Colorectal Cancer|Colorectal Adenocarcinoma |
NCT00593060 |
| Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
Head and Neck Cancer |
NCT01437449 |
| Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00097214 |
| Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer |
Active, not recruiting |
BRAF V600E-mutant Metastatic Colorectal Cancer |
NCT03693170 |
| Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer |
Withdrawn |
Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer |
NCT02573220 |
| Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma |
Recruiting |
Head and Neck Cancer|Head and Neck Squamous Cell Carcinoma|Cancer of the Head and Neck |
NCT02270814 |
| Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery |
Active, not recruiting |
Metastatic Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Squamous Cell Carcinoma|Unresectable Head and Neck Squamous Cell Carcinoma |
NCT01468896 |
| Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer |
NCT00956007 |
| Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00134069 |
| Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00985855 |
| Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA |
Recruiting |
Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Glioma|Brain Neoplasm|Brain Cancer|Brain Tumor|Brain Tumor, Recurrent|Brain Neoplasm, Malignant |
NCT02800486 |
| Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer |
Active, not recruiting |
Esophageal Neoplasm |
NCT02636088 |
| Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery |
Completed |
Colorectal Adenocarcinoma|RAS Wild Type|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7 |
NCT02292758 |
| Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status |
Recruiting |
Metastatic Colorectal Cancer |
NCT03457896 |
| EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Head and Neck |
NCT01360827 |
| S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer |
Active, not recruiting |
Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer |
NCT02438722 |
| North Carolina |
Hendersonville |
United States|Onslow Memorial Hospital |
Hendersonville |
| Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer |
Completed |
Non Small Cell Lung Cancer |
NCT00095199 |
| Colorectal Cancer (CRC) Cetuximab Elderly Frail |
Terminated |
Colorectal Cancer Metastatic |
NCT01522612 |
| Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
Completed |
Neoplasm Metastasis|Colorectal Cancer |
NCT00125034 |
| Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Cancer |
NCT00063388 |
| Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
Terminated |
Metastatic Colorectal Cancer |
NCT00531115 |
| Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer |
Completed |
Gastric Cancer |
NCT00678535 |
| Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck |
Completed |
Head and Neck Cancer |
NCT00096174 |
| Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer |
Active, not recruiting |
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7|Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 |
NCT01935921 |
| Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00479752 |
| A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel |
Withdrawn |
Lung Neoplasms|Carcinoma, Non-Small-Cell Lung |
NCT00768131 |
| A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) |
Recruiting |
Solid Tumor|Breast Cancer|Cancer of Head and Neck |
NCT02627274 |
| Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma |
Completed |
Recurrent Colorectal Carcinoma|Progressive Colorectal Carcinoma |
NCT00545545 |
| Paclitaxel/Carboplatin With or Without Cetuximab in CUP |
Unknown status |
Neoplasms, Unknown Primary|Carcinoma |
NCT00894569 |
| Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer |
Terminated |
Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer |
NCT01198535 |
| Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery |
Completed |
Esophageal Cancer |
NCT00445861 |
| Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract |
Completed |
Head and Neck Cancer|Precancerous Condition |
NCT00524017 |
| Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab |
Completed |
Colorectal Cancer |
NCT02029326 |
| Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
Recruiting |
Nasopharyngeal Carcinoma |
NCT02633176 |
| A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
Terminated |
Recurrent Head and Neck Squamous Cell Carcinoma|Metastatic Head and Neck Squamous Cell Carcinoma |
NCT01602315 |
| Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00202787 |
| Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00115518 |
| Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer |
Completed |
Lung Neoplasms|Carcinoma|Cancer of the Lung|Non-Small-Cell Lung Carcinoma |
NCT01109524 |
| Neo-adjuvant Erbitux-based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Unknown status |
Locally Advanced Malignant Neoplasm|Oral Cancer|Oropharyngeal Carcinoma |
NCT01440270 |
| Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) |
Completed |
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer |
NCT00154102 |
| Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy |
Unknown status |
Carcinoma, Squamous Cell of Head and Neck |
NCT02753140 |
| Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00061815 |
| Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer |
Unknown status |
Nasopharyngeal Carcinoma |
NCT01614938 |
| Trial of FOLF(HA)Iri With Cetuximab in mCRC |
Unknown status |
Metastatic Colorectal Cancer |
NCT02216487 |
| Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00042939 |
| Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00842257 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer |
Completed |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Advanced Adult Primary Liver Cancer|Carcinoma of the Appendix|Gastrointestinal Stromal Tumor|Metastatic Gastrointestinal Carcinoid Tumor|Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Adult Primary Liver Cancer|Recurrent Anal Cancer|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esophageal Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Extrahepatic Bile Duct Cancer|Recurrent Gallbladder Cancer|Recurrent Gastric Cancer|Recurrent Gastrointestinal Carcinoid Tumor|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Non-small Cell Lung Cancer|Recurrent Pancreatic Cancer|Recurrent Rectal Cancer|Recurrent Salivary Gland Cancer|Recurrent Small Intestine Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Small Intestine Adenocarcinoma|Small Intestine Leiomyosarcoma|Small Intestine Lymphoma|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Anal Cancer|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Colon Cancer|Stage IV Esophageal Cancer|Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IV Gastric Cancer|Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Non-small Cell Lung Cancer|Stage IV Pancreatic Cancer|Stage IV Rectal Cancer|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Unresectable Extrahepatic Bile Duct Cancer|Unresectable Gallbladder Cancer |
NCT00397384 |
| An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00207155 |
| Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies |
Completed |
Malignant Solid Tumour |
NCT00388427 |
| Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer |
Active, not recruiting |
Head and Neck Cancer|Precancerous Condition |
NCT01302834 |
| Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer |
Completed |
Breast Neoplasm |
NCT00463788 |
| An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma |
Completed |
Carcinoma, Non-Small-Cell Lung|Neoplasm Metastasis |
NCT00207116 |
| Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer |
Recruiting |
Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8 |
NCT03290937 |
| Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer |
Completed |
Cancer |
NCT00226239 |
| Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01387880 |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC |
Recruiting |
Metastatic Colorectal Cancer |
NCT04034459 |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma |
Recruiting |
Glioblastoma|Brain Cancer|Brain Neoplasm|Brain Tumor|Brain Neoplasm, Malignant|EGFR Gene Overexpression|GBM |
NCT02861898 |
| Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer |
Completed |
NSCLC |
NCT00874848 |
| Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions |
Completed |
Advanced Colorectal Cancer |
NCT00637091 |
| Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) |
Completed |
Metastatic Colorectal Cancer |
NCT00614393 |
| Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades |
Unknown status |
Pain |
NCT01693159 |
| Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC |
Recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck |
NCT03646461 |
| Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma |
Completed |
Colorectal Neoplasms|Metastases, Neoplasm |
NCT00044863 |
| A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma |
Completed |
Colorectal Carcinoma |
NCT00362102 |
| Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer |
Active, not recruiting |
Head Neck Cancer Squamous Cell Recurrent |
NCT01884623 |
| First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients |
Terminated |
Colorectal Cancer |
NCT00251186 |
| Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases |
Terminated |
Colorectal Cancer|Neoplasm Metastasis |
NCT00327093 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy |
Completed |
Recurrent Hypopharyngeal Squamous Cell Carcinoma|Recurrent Laryngeal Squamous Cell Carcinoma|Recurrent Laryngeal Verrucous Carcinoma|Recurrent Lip and Oral Cavity Squamous Cell Carcinoma|Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary|Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Recurrent Oral Cavity Verrucous Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma|Recurrent Salivary Gland Carcinoma|Salivary Gland Squamous Cell Carcinoma|Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary|Stage IV Hypopharyngeal Squamous Cell Carcinoma|Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma|Stage IVA Laryngeal Squamous Cell Carcinoma|Stage IVA Laryngeal Verrucous Carcinoma|Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Squamous Cell Carcinoma|Stage IVB Laryngeal Verrucous Carcinoma|Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVB Oral Cavity Verrucous Carcinoma|Stage IVB Oropharyngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Squamous Cell Carcinoma|Stage IVC Laryngeal Verrucous Carcinoma|Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma|Stage IVC Major Salivary Gland Carcinoma|Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma|Stage IVC Oral Cavity Verrucous Carcinoma|Stage IVC Oropharyngeal Squamous Cell Carcinoma|Tongue Carcinoma |
NCT01256385 |
| A Trial of Chemo & Radiation Therapy for Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00424827 |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT02350712 |
| S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer |
Completed |
Pancreatic Cancer |
NCT00075686 |
| A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck |
Completed |
Head and Neck Cancer |
NCT01577173 |
| Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma |
Completed |
Esophageal Cancer |
NCT00815308 |
| Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer |
Recruiting |
Colorectal Neoplasms, Malignant |
NCT03608046 |
| Cetuximab, Capecitabine and Oxaliplatin in Patients With Epidermal Growth Factor Receptor (EGFr) Expressing Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer|Neoplasm Metastasis |
NCT00444678 |
| A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer |
Terminated |
Metastatic Colorectal Cancer |
NCT01925274 |
| Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer |
Completed |
Adenocarcinoma |
NCT00395252 |
| A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver |
Completed |
Metastatic Colorectal Cancer |
NCT00803647 |
| Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00112294 |
| Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer |
Unknown status |
Metastatic Breast Cancer |
NCT00367250 |
| Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00833261 |
| Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00439608 |
| Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib |
Unknown status |
Metastatic Colorectal Cancer |
NCT00784667 |
| S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Bronchoalveolar Cell Lung Cancer|Large Cell Lung Cancer|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00368992 |
| Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery |
Active, not recruiting |
BRAF NP_004324.2:p.V600X|KRAS wt Allele|Metastatic Malignant Solid Neoplasm|Stage IV Colorectal Cancer AJCC v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Solid Neoplasm |
NCT01787500 |
| Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN |
Active, not recruiting |
Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Squamous Cell Carcinoma of the Larynx Stage III|Squamous Cell Carcinoma of the Larynx Stage IV|Squamous Cell Carcinoma of the Oropharynx Stage III|Squamous Cell Carcinoma of the Oropharynx Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV |
NCT01884259 |
| FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00501410 |
| Immunoreactivity to Cetuximab in Cancer Patients |
Completed |
Colorectal Cancer|Head and Neck Cancer |
NCT00896896 |
| Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00448838 |
| Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00868491 |
| Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00005076 |
| Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC |
Unknown status |
Carcinoma, Non-Small-Cell Lung |
NCT00561054 |
| Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery |
Completed |
Colorectal Cancer |
NCT00265811 |
| A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer. |
Active, not recruiting |
Locally Advanced Head and Neck Cancer |
NCT01969877 |
| Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT) |
Unknown status |
Glioblastoma Multiforme |
NCT00311857 |
| Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) |
Terminated |
Cancer of Larynx |
NCT00599131 |
| Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
Completed |
Colorectal Cancer |
NCT00227734 |
| A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) |
Terminated |
Pancreatic Cancer |
NCT01050426 |
| A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT01042028 |
| Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT02268695 |
| Chemotherapy, Radiation Therapy, and Cetuximab in Treating Patients With the Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00875849 |
| Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00301028 |
| A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors |
Completed |
Advanced Colorectal Cancer |
NCT00309179 |
| A Study in Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01081041 |
| Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
Completed |
Ovarian Cancer|Peritoneal Neoplasms|Fallopian Tube Neoplasms |
NCT00063401 |
| Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy |
Terminated |
Prostatic Neoplasms |
NCT00448097 |
| Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma |
Recruiting |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|KRAS Protein Variant|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 |
NCT04106362 |
| Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT02707588 |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Recurrent Non-small Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00986674 |
| Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00912327 |
| Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00640471 |
| Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer |
NCT00265941 |
| A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
Terminated |
Rectal Cancer|Colo-rectal Cancer |
NCT00226941 |
| Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC |
Terminated |
Colorectal Cancer |
NCT00755534 |
| Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
Squamous Cell Carcinoma|Head and Neck Cancer |
NCT01592721 |
| Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer |
Completed |
Pancreatic Cancer |
NCT00536614 |
| Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00629226 |
| Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab |
Completed |
Colon Cancer Liver Metastasis |
NCT01891552 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
Recruiting |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Oropharyngeal Squamous Cell Carcinoma|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8|Squamous Cell Carcinoma of Unknown Primary|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Lip and Oral Cavity Cancer AJCC v8|Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVB Hypopharyngeal Carcinoma AJCC v8|Stage IVB Laryngeal Cancer AJCC v8|Stage IVB Lip and Oral Cavity Cancer AJCC v8|Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 |
NCT03258554 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT00939627 |
| Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT00971932 |
| Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Recruiting |
Head and Neck Neoplasms |
NCT02643550 |
| Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer |
Active, not recruiting |
Esophageal Cancer |
NCT00655876 |
| Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer |
Withdrawn |
Head and Neck Cancer |
NCT00881114 |
| Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck |
Completed |
Head and Neck Cancer |
NCT00084318 |
| Chemoradiation Treatment for Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00704639 |
| Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck |
Unknown status |
Squamous Cell Carcinoma of the Head and Neck |
NCT02624128 |
| Treatment Regimens for Patients With Resectable Liver Metastases (PANTER Study) |
Terminated |
Liver Metastasis |
NCT01266187 |
| Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab |
Recruiting |
Metastatic Colorectal Cancer |
NCT02934529 |
| Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer |
Terminated |
Head and Neck Cancer|Carcinoma, Squamous |
NCT00591149 |
| Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma |
Terminated |
Rectal Cancer |
NCT00353457 |
| Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) |
Completed |
Head and Neck Cancer |
NCT00122460 |
| S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00085501 |
| Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00689624 |
| S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00288054 |
| Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) |
Completed |
Non-small Cell Lung Cancer |
NCT00097227 |
| Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00208546 |
| Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma |
Terminated |
Glioblastoma |
NCT01044225 |
| Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer |
Completed |
Cervical Cancer |
NCT00957411 |
| Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer |
Completed |
Colorectal Cancer |
NCT00084773 |
| Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer |
Completed |
Cancer |
NCT01727869 |
| A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal |
NCT00478634 |
| Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux® |
Completed |
Head and Neck Carcinoma |
NCT01228565 |
| Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer |
Unknown status |
Cervical Cancer |
NCT00997009 |
| Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer |
Completed |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer |
NCT00077298 |
| Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer |
Recruiting |
BRAF V600E Negative|KRAS Gene Mutation Negative|Locally Advanced Unresectable Colorectal Adenocarcinoma|Metastatic Colorectal Adenocarcinoma|NRAS Gene Mutation Negative|Stage III Colorectal Cancer AJCC v8|Stage IIIA Colorectal Cancer AJCC v8|Stage IIIB Colorectal Cancer AJCC v8|Stage IIIC Colorectal Cancer AJCC v8|Stage IV Colorectal Cancer AJCC v8|Stage IVA Colorectal Cancer AJCC v8|Stage IVB Colorectal Cancer AJCC v8|Stage IVC Colorectal Cancer AJCC v8 |
NCT04117945 |
| Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Head and Neck |
NCT02429089 |
| Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC |
Completed |
Non-Small Cell Lung Cancer |
NCT00828841 |
| Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin |
Completed |
Esophageal Cancer|Gastric Cancer |
NCT00397904 |
| Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients |
Completed |
Metastatic Colorectal Cancer |
NCT01030042 |
| Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy |
Unknown status |
Metastatic Colorectal Cancer|Liver Metastases|Hepatic Lesions |
NCT00852228 |
| Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00193453 |
| Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC |
Unknown status |
Metastatic Colorectal Cancer |
NCT03405272 |
| A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer |
Completed |
Gastric Cancer |
NCT00477711 |
| S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery |
Recruiting |
Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7 |
NCT03365882 |
| United States|CoxHealth South Hospital |
Missouri |
Sullivan |
Missouri |
| XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer |
Unknown status |
Colorectal Carcinoma |
NCT00215722 |
| Cetuximab in Treating Patients With Stage IV Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00020930 |
| Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) |
Completed |
Head and Neck Neoplasm |
NCT00623558 |
| Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer |
Completed |
Neoplasms, Colorectal |
NCT00540943 |
| Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) |
Completed |
Colorectal Cancer |
NCT01652482 |
| Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction |
Completed |
Adenocarcinoma of the Gastroesophageal Junction|Gastric Cancer |
NCT01360086 |
| A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin |
Completed |
Neoplasms |
NCT01482377 |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer |
Completed |
Advanced Non-Small Cell Lung Cancer |
NCT00330746 |
| Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery |
Completed |
Colorectal Cancer |
NCT00290615 |
| A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC |
Active, not recruiting |
Colorectal Cancer |
NCT03491709 |
| 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx |
Completed |
Head and Neck Cancer |
NCT00757549 |
| Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer |
Completed |
Locally Advanced Malignant Neoplasm|Oral Cancer|Oropharyngeal Carcinoma|Effects of Chemotherapy |
NCT01434394 |
| BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies |
Completed |
Colorectal Cancer |
NCT00207051 |
| Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Carcinoma |
NCT00112346 |
| SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer |
Terminated |
Colorectal Carcinoma |
NCT00361244 |
| Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016) |
Completed |
Colorectal Cancer |
NCT00925015 |
| S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer |
Terminated |
Esophageal Cancer |
NCT00109850 |
| Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery |
Terminated |
Liver Metastases|Mucinous Adenocarcinoma of the Colon|Mucinous Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Rectum|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00835679 |
| Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) |
Unknown status |
Head and Neck Cancer |
NCT01553032 |
| Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00063141 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
Unknown status |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer |
NCT01816984 |
| Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer |
Unknown status |
Rectal Neoplasms|Neoadjuvant Treatment |
NCT00506844 |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) |
Recruiting |
HNSCC |
NCT02999087 |
| Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer |
Terminated |
Esophageal Cancer |
NCT00551759 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer |
Completed |
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity|Recurrent Basal Cell Carcinoma of the Lip|Recurrent Colon Cancer|Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Recurrent Lymphoepithelioma of the Nasopharynx|Recurrent Lymphoepithelioma of the Oropharynx|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Recurrent Mucoepidermoid Carcinoma of the Oral Cavity|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Stage IV Adenoid Cystic Carcinoma of the Oral Cavity|Stage IV Basal Cell Carcinoma of the Lip|Stage IV Lymphoepithelioma of the Nasopharynx|Stage IV Lymphoepithelioma of the Oropharynx|Stage IV Mucoepidermoid Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Stage IVA Colon Cancer|Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVA Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Colon Cancer|Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVB Salivary Gland Cancer|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity|Stage IVC Salivary Gland Cancer|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Tongue Cancer |
NCT01637194 |
| Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer |
Active, not recruiting |
Anal Cancer |
NCT00316888 |
| Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC |
Withdrawn |
Liver Metastases|Colorectal Cancer |
NCT01631539 |
| Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer |
Completed |
Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum|Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage III Colon Cancer|Stage III Rectal Cancer|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00551421 |
| Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery |
Completed |
Head and Neck Cancer |
NCT00738868 |
| Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
Completed |
Colorectal Cancer|Metastatic Cancer |
NCT00056030 |
| Cetuximab & Concomitant-Boost Accelerated RT in Patients With Locally Advanced Oropharynx Squamous Cell Carcinoma. |
Unknown status |
Oropharyngeal Neoplasms |
NCT00251381 |
| Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients |
Completed |
Squamous Cell Carcinoma of the Oropharynx|HPV |
NCT01663259 |
| TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors |
Terminated |
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer |
NCT01245985 |
| High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery |
Active, not recruiting |
Lung Cancer|Radiation Toxicity |
NCT00533949 |
| Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer |
Terminated |
Head and Neck Cancer |
NCT00721513 |
| Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery |
Completed |
Pancreatic Cancer |
NCT00599833 |
| Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC) |
Completed |
Nasopharyngeal Carcinoma |
NCT01326559 |
| Cetuximab and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Oropharynx Cancer That Can Be Removed by Surgery |
Completed |
Head and Neck Cancer |
NCT00665392 |
| Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00251498 |
| Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00117962 |
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer |
Completed |
Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage II Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer |
NCT00091026 |
| A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer |
Unknown status |
Metastatic Colorectal Cancer |
NCT01801904 |
| TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers |
Recruiting |
Hepatocellular Carcinoma|Metastatic Castration Resistant Prostate Cancer|Renal Cell Carcinoma|Non-small Cell Lung Cancer|Colorectal Cancer|Squamous Cell Carcinoma of Head and Neck|Triple-Negative Breast Cancer|Urothelial Carcinoma|Cholangiocarcinoma|GastroEsophageal Cancer|Pancreatic Cancer|Sarcoma |
NCT03829436 |
| Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01086267 |
| Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) |
Completed |
Squamous Cell Carcinoma of the Hypopharynx|Larynx Carcinoma |
NCT00508664 |
| Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease |
Recruiting |
Advanced Malignant Neoplasm|Castleman Disease|Digestive System Carcinoma|Erdheim-Chester Disease|Lip and Oral Cavity Carcinoma|Lymphangioleiomyomatosis|Malignant Endocrine Neoplasm|Malignant Female Reproductive System Neoplasm|Malignant Male Reproductive System Neoplasm|Malignant Neoplasm|Malignant Respiratory Tract Neoplasm|Malignant Thoracic Neoplasm|Malignant Urinary System Neoplasm|Mesothelial Neoplasm|Metastatic Malignant Neoplasm|Metastatic Urothelial Carcinoma|Neurofibromatosis Type 2|Recurrent Adult Soft Tissue Sarcoma|Recurrent Breast Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Digestive System Carcinoma|Recurrent Female Reproductive System Carcinoma|Recurrent Male Reproductive System Carcinoma|Recurrent Malignant Neoplasm|Recurrent Pharyngeal Carcinoma|Recurrent Thyroid Gland Carcinoma|Refractory Malignant Neoplasm|Soft Tissue Neoplasm|Stage III Breast Cancer AJCC v7|Stage III Pharyngeal Cancer|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Stage IV Pharyngeal Cancer|Stage IVA Pharyngeal Cancer|Stage IVB Pharyngeal Cancer|Stage IVC Pharyngeal Cancer|Thyroid Gland Neoplasm |
NCT01552434 |
| Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00851877 |
| Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy |
Active, not recruiting |
Colorectal Cancer |
NCT01079780 |
| Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery |
Completed |
Pancreatic Cancer |
NCT00408564 |
| Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer |
Completed |
Colon Cancer |
NCT00193219 |
| Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397 |
Completed |
Head and Neck Cancer |
NCT01466244 |
| Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer |
Terminated |
Non-Small Cell Lung Cancer |
NCT01212627 |
| S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer |
Active, not recruiting |
Recurrent Large Cell Lung Carcinoma|Recurrent Lung Adenocarcinoma|Recurrent Squamous Cell Lung Carcinoma|Stage IV Large Cell Lung Carcinoma|Stage IV Lung Adenocarcinoma|Stage IV Squamous Cell Lung Carcinoma |
NCT00946712 |
| Missouri |
Billings |
United States|Northern Rockies Radiation Oncology Center |
Springfield |
| Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer |
Completed |
Liver Cancer |
NCT00483405 |
| Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases |
Active, not recruiting |
Colorectal Cancer |
NCT01802645 |
| Docetaxel+Oxali+/-Cetux Met Gastric/GEJ |
Completed |
Gastric Cancer Adenocarcinoma Metastatic |
NCT00517829 |
| A Study of Radiotherapy in Rectal Cancer Using Oxaliplatin, Capecitabine With or Without Cetuximab |
Unknown status |
Rectal Cancer |
NCT00795301 |
| Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab |
Terminated |
Colorectal Neoplasms |
NCT00321100 |
| S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer |
Completed |
Colorectal Cancer |
NCT00686166 |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment |
Completed |
Metastatic Colorectal Cancer |
NCT01134640 |
| Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy |
Terminated |
Recurrent Colon Cancer|Recurrent Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer |
NCT00499369 |
| Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Head and Neck |
NCT01015664 |
| Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Completed |
Head and Neck Squamous Cell Carcinoma |
NCT01086826 |
| Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Completed |
Carcinoma, Squamous Cell of Head and Neck |
NCT01836029 |
| Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer |
Unknown status |
Stomach Neoplasms |
NCT00384878 |
| Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT00681876 |
| Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
Completed |
Adenocarcinoma of the Lung|Adenosquamous Cell Lung Cancer|Large Cell Lung Cancer|Malignant Pleural Effusion|Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer|Stage IIIB Non-small Cell Lung Cancer|Stage IV Non-small Cell Lung Cancer |
NCT00118183 |
| Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00265850 |
| Utica |
United States|Randolph Hospital |
North Carolina |
United States|Faxton Regional Cancer Center |
| Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) |
Terminated |
Head and Neck Neoplasms |
NCT02633800 |
| Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT00719199 |
| HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver |
Completed |
Liver Cancer|Advanced Cancer |
NCT00980239 |
| Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer |
Completed |
Colorectal Cancer|Quality of Life |
NCT00079066 |
| Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
Completed |
Cervical Cancer |
NCT00101192 |
| Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma |
Withdrawn |
Carcinoma, Squamous|Squamous Cell Carcinoma|Oropharyngeal Neoplasms|Oropharyngeal Cancer |
NCT02298595 |
| A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
Terminated |
Ovarian Cancer |
NCT00082212 |
| Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT |
Completed |
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have|Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma |
NCT01931150 |
| Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
Completed |
Ovarian Cancer|Primary Peritoneal Cavity Cancer |
NCT00086892 |
| Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients |
Completed |
Pancreatic Cancer |
NCT00338039 |
| Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery |
Terminated |
Head and Neck Cancer |
NCT00646659 |
| Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery |
Completed |
Colorectal Cancer |
NCT00466505 |
| FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum |
Terminated |
Colorectal Cancer |
NCT00077233 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
Terminated |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT00906360 |
| Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery |
Completed |
Esophageal Cancer |
NCT00544362 |
| Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin |
Completed |
Advanced Biliary Cancer |
NCT00552149 |
| Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery |
Completed |
Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer |
NCT00305877 |
| Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00509561 |
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice |
Completed |
Metastatic Colorectal Cancer |
NCT01460745 |
| Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab |
Completed |
Gastrointestinal Metastatic Cancer |
NCT02845999 |
| Retrospective Study Assessing Molecular Features Predicting Response to Cetuximab |
Completed |
Colorectal Neoplasms |
NCT00491140 |
| A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer |
Unknown status |
Metastatic Colorectal Cancer |
NCT03356158 |
| FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor |
Completed |
Metastatic Colorectal Cancer |
NCT00660582 |
| EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01008475 |
| Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer |
Active, not recruiting |
Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Tongue Cancer |
NCT01810913 |
| Role of FCÎłRIIIA and FCÎłRIIA Receptor Polymorphisms |
Completed |
Upper Gingival Squamous Cell Carcinoma |
NCT01827956 |
| Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer |
Terminated |
Colon Cancer|Rectal Cancer |
NCT01126450 |
| Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer |
Completed |
Head and Neck Cancer|Precancerous Condition |
NCT01084083 |
| Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer |
Unknown status |
Colorectal Cancer|Metastatic Cancer |
NCT00482222 |
| Phase I/II Combination With Irinotecan- Erbitux |
Completed |
Metastatic Colorectal Cancer (MCRC) |
NCT00594984 |
| Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer |
Active, not recruiting |
BRAF V600E-mutant Metastatic Colorectal Cancer |
NCT02928224 |
| Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer |
Unknown status |
Colorectal Cancer |
NCT01190462 |
| A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01326000 |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
Completed |
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage IV Salivary Gland Cancer|Stage IV Squamous Cell Carcinoma of the Hypopharynx|Stage IV Squamous Cell Carcinoma of the Larynx|Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IV Squamous Cell Carcinoma of the Nasopharynx|Stage IV Squamous Cell Carcinoma of the Oropharynx|Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IV Verrucous Carcinoma of the Larynx|Stage IV Verrucous Carcinoma of the Oral Cavity|Tongue Cancer|Untreated Metastatic Squamous Neck Cancer With Occult Primary |
NCT01316757 |
| PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT02994888 |
| PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca |
Completed |
Pancreatic Cancer |
NCT00467116 |
| Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01467115 |
| Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance |
Not yet recruiting |
Skin Neoplasm |
NCT03666325 |
| Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT00736944 |
| Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment |
Terminated |
Colorectal Cancer |
NCT00538291 |
| Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer |
Completed |
Metastatic Pancreatic Cancer |
NCT01077986 |
| Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx |
Terminated |
Head and Neck Cancer |
NCT00004227 |
| Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer |
Active, not recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT01588431 |
| Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas |
Completed |
Esophageal Cancer |
NCT00319735 |
| Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung |
Completed |
Colorectal Cancer|Metastatic Cancer |
NCT00557102 |
| Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer |
Unknown status |
Incurable Colorectal Cancer|RAS-wild-type |
NCT02071069 |
| Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00640081 |
| A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Patients With Colorectal Cancer |
Completed |
Colorectal Cancer|Colorectal Carcinoma|Colorectal Tumor |
NCT00437268 |
| ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors |
Withdrawn |
Tumors |
NCT01031212 |
| Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer |
Completed |
Adenocarcinoma of the Colon|Stage III Colon Cancer |
NCT00079274 |
| Kansas City |
United States|North Kansas City Hospital |
Missouri |
United States|Liberty Radiation Oncology Clinic |
| A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab |
Not yet recruiting |
Colorectal Cancer |
NCT02515734 |
| Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
Completed |
Adenocarcinoma of the Rectum|Mucinous Adenocarcinoma of the Colon|Recurrent Colon Cancer|Recurrent Rectal Cancer|Signet Ring Adenocarcinoma of the Colon|Stage IV Colon Cancer|Stage IV Rectal Cancer |
NCT00100841 |
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer |
Completed |
Head and Neck Neoplasms |
NCT02555644 |
| Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma |
Terminated |
Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head And Neck |
NCT00903461 |
| Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas |
Withdrawn |
Pancreatic Cancer |
NCT00005591 |
| A Study in Advanced Solid Tumors |
Completed |
Solid Tumor |
NCT01063075 |
| A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer |
Completed |
Head and Neck Neoplasms |
NCT01087970 |
| Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
Squamous Cell Cancer |
NCT00705016 |
| 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) |
Unknown status |
Neoplasm Metastasis|Colorectal Cancer |
NCT00433927 |
| Investigation of the Effect of Vitamin K3-lotion for the Treatment of Cetuximab Induced Folliculitis |
Completed |
Folliculitis |
NCT01094444 |
| A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies |
Completed |
Advanced Nonhematologic Malignancies |
NCT02327169 |
| Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab |
Completed |
Advanced Cancers |
NCT00941499 |
| Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response |
Completed |
Metastatic Colon Cancer |
NCT01292356 |
| Study in Advanced Solid Tumors |
Completed |
Solid Tumor |
NCT01099358 |
| Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas |
Completed |
Malignant Gliomas |
NCT00463073 |
| Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00286130 |
| PhII ICb With/Without Erbitux in MBC Pts |
Active, not recruiting |
Metastatic Breast Cancer |
NCT00248287 |
| Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
Completed |
Metastatic Colorectal Cancer |
NCT00254137 |
| Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer |
Completed |
Esophageal Cancer |
NCT00381706 |
| Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer |
Withdrawn |
Colorectal Cancer |
NCT00571740 |
| Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC |
Unknown status |
Colorectal Cancer Metastatic |
NCT02948985 |
| Cetuximab Therapeutic Drug Monitoring in Squamous Cell Carcinoma Head and Neck Cancer Patients: Determination of the Predictive Value Exposure Levels Through a Single Arm Multicentric Study |
Recruiting |
Head and Neck Cancer |
NCT04218136 |
| A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes |
Completed |
Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer |
NCT01620242 |
| Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00842712 |
| Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District |
Recruiting |
Carcinoma of the Head and Neck |
NCT03001570 |
| Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer |
Active, not recruiting |
Gastric Cancer|Esophageal Cancer |
NCT00183898 |
| A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma |
Completed |
Oral Cancer |
NCT00933387 |
| Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery |
Completed |
Colorectal Cancer|Metastatic Cancer |
NCT00544349 |
| Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer |
Completed |
Head and Neck Cancer|Cancer of the Pharynx|Cancer of the Larynx|Nose Neoplasms|Paranasal Sinus Neoplasms|Cancer of the Oral Cavity |
NCT00462735 |
| Cetuximab Plus Combination Chemotherapy in Treating Patients With Stage IV Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00020917 |
| Sequential Treatment Strategy for Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01878422 |
| EGFR Monoclonal Antibody for Advanced Gastric Cancer |
Recruiting |
Gastric Cancer|Cetuximab|Nimotuzumab |
NCT04136600 |
| Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00005814 |
| Cetuximab and Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00559741 |
| Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy |
Completed |
Head and Neck Cancer |
NCT00004865 |
| Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer |
Completed |
Anal Cancer |
NCT00324415 |
| Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer |
Completed |
Lung Cancer |
NCT00081302 |
| Intratumoral Microdosing of TAK-981 in Head and Neck Cancer |
Not yet recruiting |
Head and Neck Cancer |
NCT04065555 |
| Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Laryngeal Squamous Cell Carcinoma Stage III|Laryngeal Squamous Cell Carcinoma Stage IV|Oropharyngeal Squamous Cell Carcinoma Stage III|Oropharyngeal Squamous Cell Carcinoma Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV|Locally Advanced Malignant Neoplasm |
NCT02236936 |
| Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer |
Completed |
Carcinoma, Non-Small-Cell Lung |
NCT00315185 |
| Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer |
Terminated |
Anal Cancer |
NCT00955240 |
| BIBW 2992 (Afatinib) in Head & Neck Cancer |
Completed |
Head and Neck Neoplasms|Carcinoma, Squamous Cell |
NCT00514943 |
| Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC |
Not yet recruiting |
Metastatic Colorectal Cancer |
NCT04224415 |
| Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc |
Terminated |
Colorectal Cancer |
NCT00755118 |
| Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract |
Completed |
Squamous Cell Carcinoma |
NCT01211938 |
| A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Neoplasms |
NCT01152437 |
| Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
Head and Neck Cancer |
NCT01412229 |
| Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT00999700 |
| Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00556413 |
| Nordic 8 - A Phase II Trial |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT01867697 |
| Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux |
Active, not recruiting |
HNSCC |
NCT00609284 |
| Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
Lung Cancer |
NCT01059188 |
| Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer |
Unknown status |
Colorectal Cancer |
NCT00392470 |
| Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT00252564 |
| MLN8237 in Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01540682 |
| Combination Chemotherapy and Cetuximab in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer |
Unknown status |
Colorectal Cancer|Peritoneal Cavity Cancer |
NCT00766142 |
| Biomarkers in Predicting Response to Cetuximab in Patients With Advanced Colorectal Cancer |
Active, not recruiting |
Colorectal Cancer |
NCT01243372 |
| Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer. |
Completed |
Breast Cancer |
NCT00600249 |
| Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer |
Unknown status |
Esophageal Cancer |
NCT00425425 |
| Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
Unknown status |
Colorectal Cancer |
NCT00182715 |
| Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab |
Unknown status |
Colorectal Cancer |
NCT01442649 |
| Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial. |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT03174405 |
| Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation |
Completed |
Larynx Cancer|Hypopharynx Cancer |
NCT00169247 |
| Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery |
Terminated |
Colorectal Cancer |
NCT00541112 |
| A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) |
Completed |
Colorectal Cancer |
NCT00497497 |
| Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer |
Unknown status |
Colorectal Cancer|Metastatic Cancer |
NCT00438737 |
| Oxaliplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients Undergoing Surgery for High-Risk Rectal Cancer |
Unknown status |
Colorectal Cancer |
NCT00383695 |
| Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer |
Unknown status |
Dermatologic Complications|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00498992 |
| Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT02255097 |
| Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
Completed |
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer |
NCT01836653 |
| Phase II Study , Association of Cisplatine Topotecan and Cetuximab in Patients Whith Late or in Progress Epithelial Cancer of the Cervix |
Terminated |
Cervix Cancer |
NCT00518193 |
| A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma |
Completed |
Head and Neck Cancer |
NCT01046266 |
| Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer |
Recruiting |
Metastatic Colorectal Cancer |
NCT03286738 |
| Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux. |
Completed |
Squamous Cell Head and Neck Carcinoma |
NCT01233843 |
| Pilot Study for Locally Advanced Head and Neck Cancer |
Withdrawn |
Head and Neck Neoplasms |
NCT01262859 |
| Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer |
Completed |
Gastric Cancer|Stomach Cancer |
NCT00857246 |
| A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer |
Terminated |
Colorectal Neoplasms |
NCT00403052 |
| Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer |
Terminated |
Head and Neck Cancer |
NCT00898742 |
| Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer |
Completed |
Dermatologic Complications|Unspecified Adult Solid Tumor, Protocol Specific |
NCT00362986 |
| Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab |
Completed |
Head and Neck Cancer |
NCT01192750 |
| A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer |
Completed |
Non-Small-Cell Lung Cancer |
NCT00867009 |
| Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma |
Terminated |
Esophageal Cancer |
NCT00735345 |
| Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane |
Recruiting |
Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head and Neck |
NCT02369458 |
| Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT01154920 |
| Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer |
Completed |
Unspecified Adult Solid Tumor, Protocol Specific |
NCT00091247 |
| Biomarkers of Response in Blood and Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer of the Head and Neck Previously Treated With Cetuximab, Cisplatin, and Radiation Therapy |
Completed |
Head and Neck Cancer |
NCT01194635 |
| C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
Completed |
Head and Neck Neoplasms |
NCT00402545 |
| Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer |
Completed |
Rectal Cancer |
NCT00972881 |
| Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer |
Completed |
Adenocarcinoma of Esophagus|Squamous Cell Carcinoma of Esophagus |
NCT00165490 |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck |
Terminated |
Squamous Cell Carcinoma of the Head and Neck|Basaloid Squamous Cell Carcinoma|Undifferentiated Carcinoma|Adenosquamous Cell Carcinoma |
NCT00570674 |
| SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03874741 |
| A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT01776307 |
| Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab |
Completed |
Advanced Malignant Neoplasm|Dermatologic Complication |
NCT01867294 |
| A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00671372 |
| A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers |
Recruiting |
Neoplasms |
NCT03783403 |
| SCT200 Injection in Patients With Head and Neck Squamous Cell Carcinoma |
Not yet recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03744208 |
| Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma |
Active, not recruiting |
Head and Neck Cancer |
NCT03713372 |
| Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma |
Unknown status |
Cholangiocarcinoma |
NCT01247337 |
| A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before |
Completed |
Non-Small Cell Lung Cancer |
NCT00870870 |
| Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma |
Unknown status |
Metastatic Head-and-neck Squamous-cell Carcinoma |
NCT02119559 |
| Pharmacokinetics and Metabolic Activation of Capecitabine |
Completed |
Metastatic Colorectal Cancer |
NCT01579357 |
| Biomarker Directed Treatment in Metastatic Colorectal Cancer |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT01703390 |
| Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) |
Completed |
Stage III Non-small Cell Lung Cancer |
NCT01102231 |
| Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC) |
Completed |
Carcinoma, Non-small-cell Lung |
NCT00406302 |
| Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer |
Withdrawn |
Head and Neck Cancer |
NCT01326468 |
| A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-NaĂŻve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab |
Withdrawn |
Colorectal Cancer |
NCT01338558 |
| Combined Anticancer Treatment of Advanced Colon Cancer |
Terminated |
Peritoneal Carcinomatosis|Colorectal Cancer Metastatic |
NCT01540344 |
| PREMIUM, Observational Study |
Unknown status |
First Line WT KRAS mCRC |
NCT01756625 |
| Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) |
Not yet recruiting |
Recurrent Head and Neck Squamous Cell Carcinoma|Head and Neck Cancer Stage IV |
NCT04282109 |
| Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 |
Recruiting |
Head and Neck Cancer|Advanced Cancer|Metastatic Cancer |
NCT03356223 |
| A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer |
Completed |
Head and Neck Neoplasms |
NCT01057589 |
| Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma (HNSCC) |
NCT02764593 |
| InductionChemo-Radio-Antibody-Treatment |
Completed |
Squamous Cell Carcinoma of the Head|Squamous Cell Carcinoma of the Neck |
NCT01181401 |
| Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer |
Completed |
Head and Neck Cancer|Head and Neck Neoplasms |
NCT00496236 |
| Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors |
Completed |
Skin Rash |
NCT00709878 |
| Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03389477 |
| Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer |
Recruiting |
Colon Cancer|Locally Advanced Malignant Neoplasm |
NCT01675999 |
| Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer |
Active, not recruiting |
Head and Neck Cancer|Carcinoma, Squamous Cell|Neoplasms, Oral|Neoplasms, Pharyngeal |
NCT03067610 |
| NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) |
Active, not recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT01950689 |
| Bevacizumab in Multiple Phase I Combinations |
Active, not recruiting |
Advanced Cancer |
NCT00543504 |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors |
Active, not recruiting |
HER2 Positive Gastric Cancer|Colorectal Cancer|Head and Neck Squamous Cell Carcinoma|EGFR Positive Solid Tumor|Advanced Solid Tumors|HER2-positive Breast Cancer|Hepatocellular Carcinoma|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Pancreatic Cancer|Melanoma |
NCT03319459 |
| Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma |
Recruiting |
Esophageal Squamous Cell Carcinoma |
NCT03817567 |
| Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT00677924 |
| Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01280643 |
| Pre-emptive Low-dose Doxycycline During Anti-EGFR Treatment |
Unknown status |
Colorectal Cancer|Skin Toxicities |
NCT01380262 |
| A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer. |
Withdrawn |
Colorectal Cancer |
NCT00577109 |
| Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer. |
Completed |
Colorectal Cancer |
NCT01691391 |
| Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project |
Terminated |
Metastatic Colorectal Cancer |
NCT00828620 |
| Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients |
Recruiting |
Colorectal Cancer|Head and Neck Cancer |
NCT01874860 |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients |
Completed |
Rash Due to Epidermal Growth Factor Receptor Inhibitors |
NCT02239731 |
| Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer |
Not yet recruiting |
Advanced Squamous Non-small Cell Lung Cancer |
NCT03808701 |
| Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors |
Not yet recruiting |
Advanced Solid Tumors |
NCT03692520 |
| A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer |
Active, not recruiting |
Neoplasm Metastasis|Colorectal Neoplasms|Breast Cancer |
NCT02124148 |
| Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer |
Unknown status |
Triple Negative Breast Neoplasms |
NCT03692689 |
| A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers |
Completed |
Multiple Myeloma, Neoplasms |
NCT01524978 |
| Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases |
Completed |
Liver Metastasis|Colorectal Cancer |
NCT01834014 |
| Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network |
Recruiting |
Colorectal Cancer Metastatic |
NCT03164655 |
| Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors |
Recruiting |
Solid Tumor |
NCT03552406 |
| Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer |
Completed |
Squamous Cell Carcinoma of the Head and Neck |
NCT03349710 |
| Study of ABT-700 in Subjects With Advanced Solid Tumors |
Completed |
Advanced Solid Tumors |
NCT01472016 |
| An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status |
Completed |
Advanced Cancers |
NCT00903734 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer |
Recruiting |
Metastatic Colorectal Cancer|Stage III Colorectal Cancer |
NCT03803553 |
| A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) |
Active, not recruiting |
Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer |
NCT02358031 |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors |
Terminated |
Neoplasms|Tumors|Solid Tumors|Metastatic Cancer |
NCT01081808 |
| Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab |
Active, not recruiting |
Dermatologic Complications|Malignant Neoplasm|Pain |
NCT01393821 |
| A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis |
Terminated |
Colorectal Cancer|Steatohepatitis |
NCT01523639 |
| Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer |
Recruiting |
Locally Advanced Head and Neck Cancer |
NCT03532737 |
| Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery |
Unknown status |
Colorectal Cancer|Metastatic Cancer |
NCT00513266 |
| Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT00003809 |
| Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer |
Terminated |
Advanced Cancer|Breast Cancer|Gastric Cancer|Esophageal Cancer|Colorectal Cancer |
NCT02318901 |
| AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer |
Withdrawn |
Metastatic Colorectal Cancer |
NCT01741038 |
| S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride |
Completed |
Colorectal Cancer|Dermatologic Complications|Lung Cancer|Therapy-related Toxicity |
NCT01416688 |
| Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis |
Recruiting |
Rectal Cancer|Liver Metastasis|Lung Metastasis |
NCT01923987 |
| A Study of LY2801653 in Advanced Cancer |
Completed |
Cancer |
NCT01285037 |
| Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) |
Active, not recruiting |
Head and Neck Cancer |
NCT03358472 |
| Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive |
Completed |
Head and Neck Neoplasms|Neoplasm Metastasis|Recurrent Disease|Progressive Disease |
NCT01737450 |
| Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) |
Active, not recruiting |
Head and Neck Squamous Cell Cancer |
NCT02252042 |
| Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer |
Unknown status |
Metastatic Colorectal Cancer |
NCT03017807 |
| FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer |
Terminated |
Recurrent Colorectal Carcinoma|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer |
NCT02508077 |
| Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement |
Terminated |
Colorectal Cancer|Metastases |
NCT00537823 |
| Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT02105636 |
| Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients |
Withdrawn |
Metastatic Colorectal Cancer |
NCT02965417 |
| Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) |
Withdrawn |
Head and Neck Cancer |
NCT03342352 |
| Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors |
Completed |
Colon Cancer, Breast Cancer, Cancer of the Head and Neck |
NCT02391727 |
| Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial |
Recruiting |
Metastatic Colorectal Cancer |
NCT03426371 |
| A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors |
Recruiting |
Metastatic Renal Cell Carcinoma|Advanced Urothelial Carcinoma|Advanced Gastric Adenocarcinoma|Metastatic Colorectal Adenocarcinoma |
NCT02599324 |
| GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors |
Recruiting |
Neoplasms |
NCT03693612 |
| Efficacy and Safety of the Prophylactic Use of Doxycycline +/- Vitamin K Cream |
Unknown status |
Metastatic Colorectal Cancer |
NCT01345526 |
| Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors |
Completed |
Metastatic Colorectal Cancer|Non-Small-Cell Lung Carcinoma |
NCT00910676 |
| Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Active, not recruiting |
Head and Neck Cancer |
NCT02741570 |
| Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) |
Recruiting |
Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of the Head and Neck|Cancer of Head and Neck|Cancer of the Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck |
NCT02573493 |
| Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG) |
Recruiting |
Metastatic Colorectal Cancer|Metastatic Head and Neck Cancer |
NCT03146338 |
| Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 |
Active, not recruiting |
Colorectal Cancer|Non-Small Cell Lung Cancer |
NCT01726309 |
| Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients |
Recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT02139020 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. |
Withdrawn |
Chordoma|Unresectable Malignant Neoplasm |
NCT03647423 |
| A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment |
Recruiting |
Colorectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Colorectal Tumors|Neoplasms, Colorectal |
NCT03428958 |
| INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer |
Completed |
Pancreatic Cancer |
NCT00322712 |
| Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model |
Recruiting |
Colo-rectal Cancer|RAS Wild-type|UICC III|UICC II + RF|UICC IV Curative Intent |
NCT03263663 |
| Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation |
Recruiting |
Radiotherapy|Colorectal Cancer|Liver Metastases |
NCT03135652 |
| Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck |
Unknown status |
Head and Neck Cancer |
NCT01133678 |
| Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03070366 |
| ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line |
Active, not recruiting |
Metastatic Colorectal Cancer |
NCT02624895 |
| Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer |
Terminated |
Lung Cancer |
NCT00569296 |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation |
Recruiting |
Advanced Solid Tumor|Non-Small Cell Lung Cancer|Colorectal Cancer |
NCT04165031 |
| Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer |
Unknown status |
Metastatic Colorectal Cancer |
NCT02211443 |
| Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial |
Unknown status |
Head and Neck Cancer |
NCT00502463 |
| AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer |
Not yet recruiting |
Colorectal Cancer Stage IV |
NCT03986541 |
| Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy |
Recruiting |
Head and Neck Cancer |
NCT03769506 |
| Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis |
Recruiting |
Rectal Cancer, Metastatic |
NCT03022734 |
| Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer |
Recruiting |
Recurrent Head and Neck Carcinoma|Locally Advanced Head and Neck Carcinoma |
NCT03727061 |
| A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) |
Completed |
Colorectal Cancer |
NCT00551213 |
| Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study |
Terminated |
Squamous Cell Carcinoma of the Head and Neck|Human Papilloma Virus |
NCT01221753 |
| A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption |
Recruiting |
Acneiform Rash|Papulopustular Eruption |
NCT03115567 |
| Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer |
Active, not recruiting |
mCRC |
NCT03567629 |
| Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer |
Recruiting |
Colorectal Cancer Metastatic |
NCT01910610 |
| A Retrospective Cohort Study of Infusion Reactions Due to Vectibix |
Completed |
Infusion Reaction |
NCT01156090 |
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) |
Active, not recruiting |
Colorectal Carcinoma |
NCT02563002 |
| Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer |
Active, not recruiting |
Head and Neck Neoplasms |
NCT01566435 |
| Anti-EGFR Immunoliposomes in Solid Tumors |
Completed |
Solid Tumors |
NCT01702129 |
| An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers |
Completed |
Solid Tumour |
NCT02648490 |
| QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed |
Active, not recruiting |
Squamous Cell Carcinoma |
NCT03387111 |
| CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. |
Unknown status |
B-cell Acute Lymphocytic Leukemia |
NCT03263208 |
| Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) |
Active, not recruiting |
Colorectal Cancer|Cancer of Pancreas|Pancreatic Neoplasm|Malignant Neoplasm of Large Intestine|Malignant Tumor of Colon|Colon Carcinoma|Cancer of Colon|Pancreatic Cancer |
NCT01420874 |
| An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck |
Withdrawn |
Head and Neck Cancer |
NCT03386838 |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy |
Withdrawn |
Head and Neck Squamous Cell Carcinoma |
NCT03169764 |
| QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC |
Withdrawn |
Colorectal Cancer |
NCT03169777 |
| Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil |
Unknown status |
Colorectal Cancer |
NCT00389870 |
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine |
Active, not recruiting |
Colorectal Cancer Metastatic|mCRC |
NCT03563157 |
| Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT02083653 |
| Sym004 Versus TAS-102 in Patients With mCRC |
Withdrawn |
Metastatic Colorectal Cancer|Colorectal Cancer Metastatic|Carcinoma |
NCT03717038 |
| QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine |
Withdrawn |
Hepatocellular Carcinoma Non-resectable|Hepatocellular Carcinoma Recurrent |
NCT03563170 |
| Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer |
Terminated |
Colorectal Cancer |
NCT01504477 |
| Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy |
Completed |
Carcinoma, Squamous Cell of Head and Neck |
NCT01417936 |
| A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer |
Not yet recruiting |
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy|Unresectable Metastatic Right-sided Colon Cancer, Stage IV |
NCT03641976 |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia |
Recruiting |
CD19+ Acute Leukemia |
NCT02028455 |
| Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer |
Completed |
Ras-wildtype Colorectal Cancer |
NCT01668498 |
| Individualized Drug Treatment for Treating Patients With Pancreatic Cancer |
Terminated |
Pancreatic Cancer |
NCT00276744 |
| The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. |
Recruiting |
Advanced Solid Tumors |
NCT03577704 |
| Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies |
Withdrawn |
Salivary Gland Malignancy |
NCT01634880 |
| Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer |
Completed |
Colorectal Neoplasms |
NCT01413295 |
| Biomarkers in Patients With Head and Neck Cancer |
Completed |
Head and Neck Cancer |
NCT01466257 |
| Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies |
Withdrawn |
Adenoma, Pleomorphic|Mixed Salivary Gland Tumor|Salivary Gland Tumor, Mixed|Syringoma, Chondroid |
NCT00984217 |
| Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal |
Recruiting |
Colorectal Cancer Metastatic |
NCT03751176 |
| Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy |
Recruiting |
HNSCC |
NCT02216916 |
| Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer |
Recruiting |
Anal Cancer |
NCT03381352 |
| Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer |
Unknown status |
Colorectal Cancer |
NCT01167725 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer |
Recruiting |
Advanced Cancer|Metastatic Melanoma|Metastatic Non-small Cell Lung Cancer|Metastatic Pancreatic Ductal Adenocarcinoma|Colorectal Cancer |
NCT02857270 |
| First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS |
Recruiting |
Metastatic Colorectal Cancer |
NCT03231722 |
| Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases |
Active, not recruiting |
Colorectal Cancer |
NCT01442935 |
| Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash |
Completed |
Acneiform Rash |
NCT01256437 |
| Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer |
Terminated |
Metastatic Cancer |
NCT03009058 |
| Targeting the Tumor Microenvironment in R/M SCCHN |
Recruiting |
Head and Neck Cancer |
NCT03844763 |
| Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors |
Terminated |
Anal, Colon, and Rectal Cancers|Head and Neck Cancer|Lung Cancer|Colon Cancer|Colonic Neoplasms|Colorectal Neoplasms|Colon/Rectal Cancer|Colon/Rectal Cancer Colon Cancer|Colon/Rectal Cancer Rectal Cancer|Colon/Rectal Cancer Anal Cancer|Head and Neck Cancers|Head and Neck Cancers Lip|Head and Neck Cancers Oral Cavity|Head and Neck Cancers Nasopharynx|Head and Neck Cancers Oropharynx|Head and Neck Cancers Hypopharynx|Head and Neck Cancers Larynx|Head and Neck Cancers Trachea|Lung Cancer Non-Small Cell Cancer (NSCLC)|Lung Cancer Small Cell Lung Cancer (SCLC) |
NCT01137162 |
| Education Intervention in Patients With Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment. |
Active, not recruiting |
Consent Form|Lung Cancer|Colon Cancer|Pancreas Cancer|Head and Neck Cancer|Breast Cancer |
NCT03992664 |
| Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor |
Unknown status |
Liver Metastasis |
NCT01511146 |
| Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma |
Terminated |
Squamous Cell Carcinoma |
NCT01009203 |
| Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer |
Completed |
Recurrent or Metastatic Head and Neck Carcinoma |
NCT02347332 |
| A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) |
Active, not recruiting |
Colorectal Cancer |
NCT02291289 |
| A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors |
Recruiting |
Advanced Solid Tumors |
NCT02671435 |
| Study of Target-Guided Chemotherapy in Metastatic Colorectal Patients |
Completed |
Progression Free Survival |
NCT01453257 |
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) |
Not yet recruiting |
Colorectal Cancer Metastatic |
NCT04031872 |
| Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies |
Completed |
Hypomagnesemia |
NCT02690012 |
| Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
Unknown status |
Non-small Cell Lung Cancer |
NCT00950365 |
| Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy |
Completed |
Colorectal Cancer |
NCT00713128 |
| Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC) |
Completed |
Metastatic Colorectal Cancer |
NCT00862342 |
| High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents |
Completed |
Metastatic Breast Cancer |
NCT01414933 |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer |
Withdrawn |
Colorectal Cancer Metastatic |
NCT03470350 |
| Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors |
Not yet recruiting |
Advanced Tumors |
NCT04151810 |
| Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer |
Active, not recruiting |
Head and Neck Carcinoma |
NCT02718820 |
| A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma |
Recruiting |
Prosthesis Survival |
NCT02409186 |
| Change in Body Weight During Treatment of Advanced Colorectal Cancer |
Recruiting |
Cancer, Colorectal|Chemotherapy Effect|Weight Loss|Prognosis |
NCT04232748 |
| Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer |
Completed |
Metastatic or Recurrent Colorectal Cancer|Refractory to Fluoropyrimidine, Oxaliplatin and Irinotecan|Salvage Chemotherapy |
NCT01409005 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults |
Recruiting |
Pediatric Solid Tumor|Germ Cell Tumor|Retinoblastoma|Hepatoblastoma|Wilms Tumor|Rhabdoid Tumor|Carcinoma|Osteosarcoma|Ewing Sarcoma|Rhabdomyosarcoma|Synovial Sarcoma|Clear Cell Sarcoma|Malignant Peripheral Nerve Sheath Tumors|Desmoplastic Small Round Cell Tumor|Soft Tissue Sarcoma|Neuroblastoma |
NCT03618381 |
| Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy |
Completed |
Head and Neck Cancer |
NCT01955239 |
| A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer |
Recruiting |
Colorectal Cancer|Colorectal Carcinoma|Colorectal Adenocarcinoma|Refractory Cancer|Colorectal Neoplasms |
NCT03206073 |
| Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer |
Unknown status |
Resectable Hepatic Metastases of Colorectal Cancer |
NCT01673607 |
| Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC |
Recruiting |
Stage III Esophageal Squamous Cell Carcinoma |
NCT02812641 |
| Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer |
Not yet recruiting |
Rectal Cancer |
NCT04215731 |
| Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers |
Withdrawn |
Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Head and Neck Cancer |
NCT03323424 |
| Olaparib and Radiotherapy in Head and Neck Cancer |
Recruiting |
Laryngeal Cancer Stage II|Laryngeal Cancer Stage III|Carcinoma, Squamous Cell|Head and Neck Neoplasms |
NCT02229656 |
| Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients |
Unknown status |
Colorectal Cancer|KRAS Wildtype|After Resection of Liver Metastases |
NCT01384994 |
| Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours |
Unknown status |
Focus of Study Instead |
NCT01728818 |
| Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) |
Terminated |
Neoplasms |
NCT00954512 |
| INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy |
Recruiting |
Head and Neck Squamous Cell Carcinoma |
NCT03953976 |
| Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer |
Unknown status |
Colorectal Cancer |
NCT01895257 |
| Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer |
Completed |
Colorectal Cancer |
NCT00975897 |
| Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma |
Completed |
Carcinoma, Colorectal |
NCT01380600 |
| Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Routine Clinical Practice |
Completed |
Type 1 Diabetes Mellitus |
NCT03793283 |
| Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status |
Recruiting |
Advanced Colorectal Cancer |
NCT04252456 |
| Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck |
Not yet recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT03513042 |
| Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer |
Completed |
Metastatic Colorectal Cancer |
NCT01791309 |
| Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer |
Recruiting |
Colorectal Cancer Metastatic |
NCT03251612 |
| Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases |
Withdrawn |
Metastatic Liver Cancer|Secondary Liver Cancer|Liver Neoplasm |
NCT00510627 |
| mXELOXIRI Combined With Molecular Targeted Drug in mCRC |
Recruiting |
Unresectable Metastatic Colorectal Cancer |
NCT04160416 |
| A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors |
Completed |
Advanced Solid Tumor |
NCT00502567 |
| Study of Therapeutic Targets Tailored Ch and IMRT as Neoadjuvant Treatment in Rectal Carcinoma Patients |
Completed |
Rectal Cancer |
NCT01366118 |
| De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study |
Active, not recruiting |
Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms |
NCT02281955 |
| Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Recruiting |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer |
NCT03768375 |
| Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery |
Active, not recruiting |
Colorectal Cancer |
NCT00647530 |
| RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO) |
Not yet recruiting |
Metastatic Colorectal Cancer |
NCT03259009 |
| Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases |
Unknown status |
Colorectal Cancer|Liver Tumor |
NCT01677728 |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer |
Recruiting |
Metastatic Colorectal Cancer|MSI |
NCT03186326 |
| OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - |
Recruiting |
Colorectal Cancer Metastatic|Circulating Tumor DNA|KRAS Gene Mutation|NRAS Gene Mutation|BRAF Gene Mutation|Epidermal Growth Factor Receptor Inhibitor |
NCT03750175 |
| Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer |
Recruiting |
Advanced Colorectal Cancer |
NCT03311750 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) |
Active, not recruiting |
Cancer|Solid Tumor |
NCT01848834 |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer |
Active, not recruiting |
Squamous Cell Carcinoma of the Head and Neck |
NCT02551159 |
| Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery |
Completed |
Head and Neck Squamous Cell Carcinoma|Growth Factor|Surgery |
NCT01280318 |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Recruiting |
Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer |
NCT02836847 |
| A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) |
Recruiting |
Metastatic Colorectal Cancer |
NCT04008030 |
| Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
Completed |
Adenocarcinoma of Colon|Adenocarcinoma of Rectum|Metastatic Disease |
NCT01703910 |
| Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver |
Recruiting |
Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma |
NCT03366155 |
| A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors |
Terminated |
Neoplasms |
NCT00811993 |
| Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer |
Completed |
Lung Cancer|Non-small Cell Lung Cancer (NSCLC) |
NCT00323869 |
| CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer |
Recruiting |
Metastatic Colorectal Cancer |
NCT03206151 |
| A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma |
Recruiting |
Colorectal Cancer|Cholangiocarcinoma |
NCT03693807 |
| Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma |
Active, not recruiting |
Follicular Lymphoma |
NCT00115700 |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy |
Completed |
Metastatic Cancer |
NCT02142036 |
| P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC |
Recruiting |
Carcinoma, Squamous Cell|Head and Neck Neoplasms|Oropharyngeal Neoplasms |
NCT03077243 |
| Anticancer Vigilance Of Cardiac Events (AVOCETTE) in Metastatic Colorectal Cancer |
Not yet recruiting |
Colorectal Cancer Metastatic |
NCT03923036 |
| Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Completed |
Head and Neck Cancer |
NCT01054625 |
| CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy |
Not yet recruiting |
Nasopharyngeal Carcinoma |
NCT03529279 |
| Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors |
Completed |
Metastatic Colorectal Cancer |
NCT01927341 |
| A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors |
Completed |
Advanced Cancer |
NCT02014909 |
| Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities |
Terminated |
Advanced or Metastatic Solid Malignancy |
NCT01758575 |
| Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer |
Completed |
Recurrent Head and Neck Cancer |
NCT02422979 |
| Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers |
Recruiting |
Acute Myelogenous Leukemia|Ovarian Cancer|Colorectal Cancer|Triple-negative Breast Cancer|Small-cell Lung Cancer |
NCT03761914 |
| Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma |
Completed |
Colorectal Carcinoma|CRC |
NCT01394939 |
| Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation |
Completed |
Oral Mucositis |
NCT02630004 |
| CD19-Specific T Cells Post AlloSCT |
Not yet recruiting |
Acute Lymphoblastic Leukemia|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|CD19 Positive|Chronic Lymphocytic Leukemia|Minimal Residual Disease|Non-Hodgkin Lymphoma|Small Lymphocytic Lymphoma |
NCT03579888 |
| Biomarker-based Study in R/M SCCHN |
Recruiting |
Carcinoma, Squamous Cell of Head and Neck |
NCT03088059 |
| Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) |
Terminated |
Amyotrophic Lateral Sclerosis |
NCT00818389 |
| Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy |
Completed |
Myasthenia Gravis |
NCT00294658 |
